YAP1 and breast cancer: Inhibition of MAP3K3 by shRNA transduction or ponatinib treatment suppressed YAP-dependent resistance to the CDK4/6 inhibitor palbociclib, which is a mainstay targeted therapy for hormone-positive HER2-negative breast cancers.